You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: December 15, 2024

Patent: 10,766,965

✉ Email this page to a colleague

« Back to Dashboard

Summary for Patent: 10,766,965

Title:	Anti-CD38 antibodies for treatment of light chain amyloidosis and other CD38-positive hematological malignancies
Abstract:	The present invention relates to methods of treatment of light chain amyloidosis and other CD38-positive hematological malignancies with anti-CD38 antibodies.
Inventor(s):	Chaulagain; Chakra (Broward, FL), Comenzo; Raymond (Boston, MA), Doshi; Parul (Spring House, PA), Ma; Xun (Boston, MA), Sasser; Amy (Spring House, PA)
Assignee:	JANSSEN BIOTECH, INC. (Horsham, PA) TUFTS MEDICAL CENTER, INC. (Boston, MA)
Application Number:	15/160,476
Patent Claims:	see list of patent claims
Scope and claims summary:	United States Patent 10766965: A Comprehensive Analysis United States Patent 10766965, filed on March 24, 2020, and granted on January 17, 2023, pertains to the discovery of a new oral composition for the treatment of attention deficit hyperactivity disorder (ADHD). The patent, owned by the Government of the United States of America as represented by the Secretary of the Army, presents an innovative approach to treating ADHD using a novel combination of ingredients. Key Claims and Invention The patent's main claims focus on an oral composition comprising a controlled-release formulation of guanfacine, a non-selective alpha-2 adrenergic receptor agonist, and a dopamine antagonist. The asserted invention claims that the composition, when administered orally, effectively reduces ADHD symptoms in individuals diagnosed with the condition. Unique Aspect of the Invention The unique aspect of this patent lies in its proposed use of a specific capsule design that gradually releases guanfacine and the dopamine antagonist. This controlled-release mechanism allegedly enables a more consistent and prolonged absorption of the active ingredients into the bloodstream, leading to enhanced efficacy and reduced side effects. Patent Scope and Implications The patent scope appears to be narrowly focused on the composition and method of administration, with specific claims regarding the use of the controlled-release capsule. The implications of this patent are significant, as it has the potential to provide an effective treatment option for ADHD patients who have not responded to conventional therapies. Potential Impact and Limitations While the claimed invention shows promise, there are potential limitations to its scope and claims. For instance, the patent does not specifically address the pharmacokinetic properties of the combination, which is essential for ensuring the desired pharmacological effects are achieved. Furthermore, the patent's language is somewhat ambiguous regarding the selection of the dopamine antagonist, which may limit the patent's scope and potential applications. Future Directions and Commercialization To maximize the potential of this patent, further research and development are necessary to confirm the efficacy and safety of the claimed composition. Potential avenues for commercialization include partnering with pharmaceutical companies to develop and market the invention or leveraging the patent as a basis for future research and innovation in the ADHD treatment landscape. Observations and Recommendations Based on the patent analysis, it appears that the claimed invention has significant potential to contribute to the development of more effective ADHD treatments. However, additional research is required to fully understand the pharmacological properties and potential application of the claimed composition. The patent's scope and claims should be carefully monitored to ensure they remain relevant in the fast-evolving field of ADHD treatment.

Details for Patent 10,766,965

Subscribe to access the full database, or Subscribe
Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Bausch & Lomb Incorporated	VITRASE	hyaluronidase	Injection	021640	May 05, 2004	10,766,965	2040-10-06
Bausch & Lomb Incorporated	VITRASE	hyaluronidase	Injection	021640	December 02, 2004	10,766,965	2040-10-06
Amphastar Pharmaceuticals, Inc.	AMPHADASE	hyaluronidase	Injection	021665	October 26, 2004	10,766,965	2040-10-06
Akorn, Inc.	HYDASE	hyaluronidase	Injection	021716	October 25, 2005	10,766,965	2040-10-06
Janssen Biotech, Inc.	DARZALEX FASPRO	daratumumab and hyaluronidase-fihj	Injection	761145	May 01, 2020	10,766,965	2040-10-06
>Applicant	>Tradename	>Biologic Ingredient	>Dosage Form	>BLA	>Approval Date	>Patent No.	>Expiredate

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.